PURPOSE: Although glucose is the main source of energy for the human brain, ketones play an important role during starvation or injury. The purpose of our study was to investigate the metabolic effects of a novel hypertonic sodium ketone solution in normal animals. METHODS: Adult Sprague-Dawley rats (420-570 g) were divided into three groups of five, one control and two study arms. The control group received an intravenous infusion of 3 % NaCl at 5 ml/kg/h. The animals in the two study arms were assigned to receive one of the two formulations of ketone solutions, containing hypertonic saline with 40 and 120 mmol/l beta-hydroxybutyrate, respectively. This was infused for 6 h and then the animal was euthanized and brains removed and frozen. RESULTS: Both blood and cerebrospinal fluid (CSF) levels of beta-hydroxybutyrate (BHB) demonstrated strong evidence of a change over time (p < 0.0001). There was also strong evidence of a difference between groups (p < 0.0001). Multiple comparisons showed all these means were statistically different (p < 0.05). Measurement of BHB levels in brain tissue found strong evidence of a difference between groups (p < 0.0001) with control: 0.15 mmol/l (0.01), BHB 40: 0.19 mmol/l (0.01), and BHB 120: 0.28 mmol/l (0.01). Multiple comparisons showed all these means were statistically different (p < 0.05). There were no differences over time (p = 0.31) or between groups (p = 0.33) or an interaction between groups and time (p = 0.47) for base excess. CONCLUSION: The IV infusions of hypertonic saline/BHB are feasible and lead to increased plasma, CSF and brain levels of BHB without significant acid/base effects.
PURPOSE: Although glucose is the main source of energy for the human brain, ketones play an important role during starvation or injury. The purpose of our study was to investigate the metabolic effects of a novel hypertonic sodium ketone solution in normal animals. METHODS: Adult Sprague-Dawley rats (420-570 g) were divided into three groups of five, one control and two study arms. The control group received an intravenous infusion of 3 % NaCl at 5 ml/kg/h. The animals in the two study arms were assigned to receive one of the two formulations of ketone solutions, containing hypertonic saline with 40 and 120 mmol/l beta-hydroxybutyrate, respectively. This was infused for 6 h and then the animal was euthanized and brains removed and frozen. RESULTS: Both blood and cerebrospinal fluid (CSF) levels of beta-hydroxybutyrate (BHB) demonstrated strong evidence of a change over time (p < 0.0001). There was also strong evidence of a difference between groups (p < 0.0001). Multiple comparisons showed all these means were statistically different (p < 0.05). Measurement of BHB levels in brain tissue found strong evidence of a difference between groups (p < 0.0001) with control: 0.15 mmol/l (0.01), BHB 40: 0.19 mmol/l (0.01), and BHB 120: 0.28 mmol/l (0.01). Multiple comparisons showed all these means were statistically different (p < 0.05). There were no differences over time (p = 0.31) or between groups (p = 0.33) or an interaction between groups and time (p = 0.47) for base excess. CONCLUSION: The IV infusions of hypertonic saline/BHB are feasible and lead to increased plasma, CSF and brain levels of BHB without significant acid/base effects.
Authors: Ali Salim; Pantelis Hadjizacharia; Joseph Dubose; Carlos Brown; Kenji Inaba; Linda S Chan; Daniel Margulies Journal: Am Surg Date: 2009-01 Impact factor: 0.688
Authors: S G Hasselbalch; G M Knudsen; J Jakobsen; L P Hageman; S Holm; O B Paulson Journal: J Cereb Blood Flow Metab Date: 1994-01 Impact factor: 6.200
Authors: Giuseppe Citerio; Jan Bakker; Matteo Bassetti; Dominique Benoit; Maurizio Cecconi; J Randall Curtis; Glenn Hernandez; Margaret Herridge; Samir Jaber; Michael Joannidis; Laurent Papazian; Mark Peters; Pierre Singer; Martin Smith; Marcio Soares; Antoni Torres; Antoine Vieillard-Baron; Jean-François Timsit; Elie Azoulay Journal: Intensive Care Med Date: 2013-12-13 Impact factor: 17.440
Authors: Nino Stocchetti; Fabio S Taccone; Giuseppe Citerio; Paul E Pepe; Peter D Le Roux; Mauro Oddo; Kees H Polderman; Robert D Stevens; William Barsan; Andrew I R Maas; Geert Meyfroidt; Michael J Bell; Robert Silbergleit; Paul M Vespa; Alan I Faden; Raimund Helbok; Samuel Tisherman; Elisa R Zanier; Terence Valenzuela; Julia Wendon; David K Menon; Jean-Louis Vincent Journal: Crit Care Date: 2015-04-21 Impact factor: 9.097
Authors: Jan Wernerman; Kenneth B Christopher; Djillali Annane; Michael P Casaer; Craig M Coopersmith; Adam M Deane; Elisabeth De Waele; Gunnar Elke; Carole Ichai; Constantine J Karvellas; Stephen A McClave; Heleen M Oudemans-van Straaten; Olav Rooyackers; Renee D Stapleton; Jukka Takala; Arthur R H van Zanten; Paul E Wischmeyer; Jean-Charles Preiser; Jean-Louis Vincent Journal: Crit Care Date: 2019-09-18 Impact factor: 9.097
Authors: Susan A Masino; David N Ruskin; Natalie R Freedgood; Marie Lindefeldt; Maria Dahlin Journal: Nutr Metab (Lond) Date: 2021-03-01 Impact factor: 4.169